]>
IRCT20150923024147N1 IRCT 2019-02-04 Tehran University of Medical Sciences Excimer Laser in Alopecia Areata Comparison of the Effectiveness of 308-nm Xenon Chloride Excimer Laser on the Treatment of Patchy Alopecia Areata 2019-04-04 anticipated 35 Complete https://irct.ir/trial/36911 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Randomization description: One of the lesions that has the inclusion criteria is undergone the beam of excimer radiation by use of permuted block randomization. And one of the other lesions is considered as a control for steroid injection, Blinding description: Two dermatologists evaluated the photographs and phototrichograms of three assessments of the baseline, after the last treatment session, and after one month of follow-up blindly. N/A Alopecia Areata. Intervention 1: Intervention group: another category of the lesions are treated with an excimer laser treatmentThe patient will visit the center for 12 sessions (once a week). In each session, the patient's lesion that was selected based on the initial blockage, is irradiated by the excimer laser beam .The laser start dose is 100 to 200 milijoule, depending on the skin type and increases by as much as 100 milijoule per square centimeter in each volume. In the event of complications such as laser-induced burns, the laser treatment of that session is discontinued and after the necessary steps and treatment with topical steroids in the next session, the dosage would be reduced by 100 mJ in the next session. Intervention 2: Control group: Patients' lesions are divided into two groups: one treatment group, corticosteroid injections (40 mg/ml triamcinolone acetonide diluted with lidocaine or distilled water) are treated monthly with 5 mg/ml in 3 sessions(once a month) for the patient. Yes - There is a plan to make this available What will be shared: All patient information can be shared without naming and identifying them. When: Details of the data are immediately available after publishing the results. To whom: All researchers and health professionals working in academic, scientific and medical institutions. Conditions: The data is only shared for person whose purpose is to improve the therapeutic course of alopecia areata. Any The type of statistical analysis can be done in order to improve the treatment. Where to obtain: Tehran University of Medical Sciences professor Maryam Daneshpazhooh Dermatologist Razi hospital, Wahdat-e-Islami Ave., Tehran, District 12 Phone number: +98 912 130 6662 Email: maryamdanesh.pj@gmail.com How to obtain: Information is available immediately after verifying that the applicant's circumstances are met by the competent authorities. Comments:
public Nika Kianfar
Razi hospital, Wahdat-e-Islami Ave., Tehran, District 12
Tehran Iran (Islamic Republic of) 1199663911 +98 21 5561 8989 Nika_kianfar@yahoo.com Tehran University of Medical Sciences scientific Maryam Daneshpazhooh
Razi hospital, Wahdat-e-Islami Ave., Tehran, District 12
Tehran Iran (Islamic Republic of) 1199663911 +98 21 5560 9951 maryamdanesh.pj@gmail.com Tehran University of Medical Sciences Iran (Islamic Republic of) clinical diagnosis of alopecia areata by a dermatologist Having at least 2 lesions or more (multiple-patchy) in the face or scalp The size of the lesions is at least 2 cm in 2 cm has not used a drug for the lesions, In the last 3 months 18 years 60 years Both Having alopecia totalis or alopecia universalis or ophiasis Pregnancy breast feeding An underlying disease such as endocrine diseases or immonological disorders causes hair loss If hair loss has a cause other than alopecia areata. Taking a drug (systemically or topical) causes hair loss or hair regrowth in the last 3 months Surgical treatment such as hair transplantation for the treatment of hair loss. Any dermatological diseases such as skin cancer, infection which can cause hair loss Photosensivity If the patient becomes pregnant during the study patients unwillingness to continue cooperation in the clinical trial Progression of disease during the clinical trial L63 Alopecia areata Treatment - Devices Treatment - Drugs Intervention group: another category of the lesions are treated with an excimer laser treatmentThe patient will visit the center for 12 sessions (once a week). In each session, the patient's lesion that was selected based on the initial blockage, is irradiated by the excimer laser beam .The laser start dose is 100 to 200 milijoule, depending on the skin type and increases by as much as 100 milijoule per square centimeter in each volume. In the event of complications such as laser-induced burns, the laser treatment of that session is discontinued and after the necessary steps and treatment with topical steroids in the next session, the dosage would be reduced by 100 mJ in the next session Control group: Patients' lesions are divided into two groups: one treatment group, corticosteroid injections (40 mg/ml triamcinolone acetonide diluted with lidocaine or distilled water) are treated monthly with 5 mg/ml in 3 sessions(once a month) for the patient. The percentage of hair regrowth. Timepoint: At at baseline, after the last treatment session (session 12); and after one month of follow-up, the percentage of hair regrowth is measured. Method of measurement: 1.By phototrichogram(fotofinder) device. 2.by Photographic evaluation by 2 other dermatologists 3.By general assessment of the patient. Tehran University of Medical Sciences Approved 2019-01-12 Ethics committee of Tehran University of Medical Sciences No. 1, Poorsina Ave., Ghods Ave., Enghelab Ave. Tehran Tehran Iran (Islamic Republic of)